Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Health Check: Liberation Day Temporarily Shields the Global Pharmaceutical Industry

April 01, 2025 02:00 AM CEST | By Team Kalkine Media
Health Check: Liberation Day Temporarily Shields the Global Pharmaceutical Industry
Image source: shutterstock

Recent News

thumbnail

Rajd Beskidy Returns with a ‘Devilishly Tough’ Course in Poland and Sl...

thumbnail

Cargoos Introduces Operational Branding Framework That Embeds Trust in...

thumbnail

Scalo Relocates to New Office Space in Warsaw

thumbnail

Wytrwal Industries Celebrates 200 Years of KeyBank

Highlights

  • Pharmaceuticals granted temporary exemption from US tariffs, with future policies under review.

  • ASX medical device companies adjusting manufacturing strategies to address tariff-related challenges.

  • Advancements in clinical trials and supply agreements shaping ASX biotech companies.

The pharmaceutical industry has received a temporary exemption from US tariffs, but discussions regarding future tariff applications persist. Pharmaceuticals exported from Europe into the US could face a baseline tariff. Australian-listed CSL (ASX:CSL) exports products derived from blood collection and continues to assess the effects of evolving US tariff policies on its operations.

Adjustments in Medical Device Manufacturing

Medical device manufacturers listed on the ASX are actively addressing the impact of tariffs on US-bound exports by evaluating local production options. Ansell (ASX:ANN), which operates manufacturing facilities in China, has been subject to a tariff, leading to a review of its pricing structure. In response, the company has announced price adjustments to offset costs. Cyclopharm (ASX:CYC) and EBR Systems (ASX:EBR) have expanded their US-based manufacturing capabilities to mitigate tariff-related issues. Compumedics (ASX:CMP) continues to monitor tariff policies to determine future manufacturing strategies. ResMed (ASX:RMD), which has lower reliance on China-based production, may experience a shift in its competitive standing within the sector.

Developments in Biotech Trials and Agreements

Orthocell (ASX:OCC) is progressing toward US regulatory approval for its nerve repair device, Remplir, following previous approvals in Australia and New Zealand. Race Oncology (ASX:RAC) has initiated a phase I trial for its drug RC-220, aimed at expanding its clinical development pipeline. Imugene (ASX:IMU) is advancing its dosage research within a US-based CD-19 biomarker trial. Bioxyne (ASX:BXN) has finalized a supply agreement, leading to an increase in revenue from a key business partner. These advancements illustrate the ongoing development across ASX-listed biotechnology companies amid broader industry adjustments.

 

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles